Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Strata Critical Medical, Inc. Class A Common Stock

$5.79

+0.01 (+0.17%)

Market Cap
351.44 M
EPS
-0.19
P/E Ratio
-21.42 $
Value Trade
4.50 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    67.38 M

  • Operating CF

    3.88 M

  • Total Assets

    327.62 M

  • Total Liabilities

    41.89 M

  • Equity

    285.73 M

  • D/E Ratio

    12,345

%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Profitable

  • Cash Position

    58.79 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 6, 2026
Overview
Volume
1.66 M
52 Week Range
2.51 - 6.02
% held by Insiders
24.03 %
% held by Institutions
62.73 %
Enterprise Value
293.25 M
Total Shares
86.98 M
Short %
7.59 %
Float Shares
62.36 M
Company Description
HQ: 666 THIRD AVENUE, NEW YORK, NY...
Employees:601
https://www.stratacritical.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in SRTA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SRTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SRTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SRTA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
SRTA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
SRTA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-SRTA
May 7, 2026
SRTAGeneral

Strata Critical Medical Announces Expiration of Warrants

Strata Critical Medical, Inc. announced the expiration of its Public and Private Placement Warrants on May 7, 2026. This expiration occurred in accordance with the original terms set for these financial instruments. Strata operates a significant logistics and medical services network in the U.S. healthcare sector, focusing on transplant services.

Read more →
-SRTA
May 6, 2026
SRTAGeneral

Strata Critical Medical Announces First Quarter 2026 Results

Strata Critical Medical reported a strong financial performance for Q1 2026, with revenues rising 87.4% year-over-year to $67.4 million. The company experienced notable growth in both logistics and clinical segments, alongside the successful acquisition of Ohio Valley Perfusion Associates. Despite some challenges, including a slight decline in logistics revenue due to external factors, Strata remains optimistic about its growth trajectory and operational improvements.

Read more →
Competitive Position
How SRTA ranks across every disease it competes in
Competitive Position is a premium feature
See how SRTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial